Our findings reinforce the usefulness of CD169 RMFI at patient admission, along with T- and B-lymphocyte immunophenotyping, providing a reliable early measurement of immune status and assessment of COVID-19 disease progression to potentially drive the therapeutic approach. This evidence concerns the gene SIGLEC1 and COVID-19.